Table 4 Data availability of pharmaceutical companies displaying certification via PhRMA or EFPIA websites which solicit data requests via online data sharing platform [47, 83, 84]
Pharmaceutical company | Clinical data made available | Publicized date of earliest available data |
|---|---|---|
Request point:https://clinicalstudydatarequest.com [52] | ||
Phase 1, 2, 3 and 4 studies for indications which have been approved by the US and, or EU | January 1, 2010 | |
Bayer [56] | All trials required for regulatory approval | January 1, 2014 |
Chugai [86] | All sponsored clinical trials | January 1, 2014 |
Eisai [61] | Phase 2, 3 and 4 studies required for regulatory approval which have been approved by the US and, or EU. | January 1, 2014 |
All global interventional studies All interventional studies since 2013 Other studies where data are provided to researchers | December 1, 2000 | |
Novartis [89] | Phase 2 and 3 studies required for regulatory approval in the EU or US Requested studies must support the indication | January 1, 2014 |
Roche [75] | All phase 2 and 3 studies or phase 4 studies required for regulatory approval. Products terminated from development. | January 1, 1999 |
Sanofi [67] | All trials, for approved indications, required for regulatory approval in the US and EU | January 1, 2014 |
Shionogi {Shionogi & Co. Ltd., 2018 #3717} | Phase 1, 2, 3, and 4 studies used for regulatory approval in the US, EU, and Japan | February 1, 2019 |
Sumitomo Dainippon Pharma Co, Ltd. [90] | Phase 2, 3, and 4 interventional clinical studies included in the submission package for approved medications in the US, EU, or Japan | January 1, 2014 |
UCB [70] | Phase 2, 3, and 4 study data for approved medicines and indications | November 1, 2008 |
Viiv Healthcare [65] | Phase 2, 3, and 4 study data for approved medications | November 1, 2017 |
Research fundersa | Phase 1, 2, 3, and 4 interventional clinical studies Phase 1, 2, 3, and 4 interventional clinical studies for terminated compounds | January 1, 2010 |
Request point: https://yoda.yale.edu/how-request-data [91] | ||
Phase 2, 3 and 4 studies for products approved in the US and EU | January 1, 1990b | |
Request point:https://vivli.orgc [80] | ||
Abbvie [53] | Phase 2, 3 and 4 interventional clinical studies for medicinal products and indications which received authorization in US or EU | May 1, 2004 |
Biogen [94] | Phase 1, 2, 3 and 4 interventional clinical trials for products and indications submitted to and approved in the US and EU. | January 1, 2004 |
Boehringer Ingelheim [58] | All trials with published results | January 1, 1998 |
Studies supporting indications approved in the US and EU | January 1, 2014 | |
Daiichi-Sankyo [96] | Phase 2, 3 and 4 interventional clinical studies submitted for approved medications in US, EU or Japan | January 1, 2014 |
Global interventional studies Interventional studies evaluating medicines, starting in or after 2013 Consumer healthcare studies completed on or after January 1, 2018 | December 1, 2000 | |
Phase 2, 3 and 4 studies for products approved in the US and EU | January 1, 1990b | |
Lilly [63] | Phase 2, 3 and 4 studies submit for regulatory approval to FDA on or after 1999 Phase 2, 3, 4 global studies after January 2007 Phase 2, 3, 4 regional studies for drugs approved in US and EU since January 1, 2014 | January 1, 1999 |
Global interventional studies conducted for medicines, vaccines, and medical devices which were terminated or are approved in the US or EU | September 1, 2007 | |
Takeda [70] | Phase 1,2,3 and 4 trials which support products approved in the US, EU, and/or Japan and products terminated from development | January 1, 2005 |
UCB [70] | Phase 2, 3, and 4 study data for medicines and indications approved in the US and EU | January 1, 2007 |
Request point:https://astrazenecagroup-dt.pharmacm.com/DT/Home/Login | ||
Phase 1, 2, 3, or 4 studies for approved indications in the US, EU, or Japan | January 1, 2009* | |
Request point: https://biogen-dt-external.pharmacm.com/DT/Home | ||
Biogen [57] | Phase 1, 2, 3, or 4 studies for discontinued compounds or those approved in the US and EU | January 1, 2014 |
Request point:https://fasttrack.force.bms.com/ | ||
Phase 1, 2, 3, or 4 study data for medicines and indications approved in the US or EU | January 1, 2008 | |
Request point: https://www.celgeneclinicaldatasharing.com | ||
Study data for compounds and indications approved in the US and EU | January 1, 2014 | |
Request point:http://www.chiesi.com/en/chiesi-clinical-trial-data-request-portal/ | ||
Chiesi [102] | Study data for medications approved by the FDA or EMA | January 1, 2015 |
Study data for products and indications approved in the US and EU | January 1, 2014 | |
Request point:https://clinicaltrials.menarini.com/en-US/Home/Register | ||
Study data for medications and indications approved in the US and EU | Unclear | |
Request point:http://engagezone.msd.com/ | ||
Merck & Co. [73] | Study data submit for regulatory approval in the US and EU for approved indications | September 1, 2007 |
Request point:https://www.purduepharma.com/healthcare-professionals/clinical-trials/#request-trial-data | ||
Purdue Pharmaceuticals [74] | Phase 2, 3 or 4 study data for drug products and their approved uses in the US for approved indications | January 1, 2014 |
Request point: https://errs.regeneron.com/external | ||
Regeneron [106] | Approved medicines and indications with publicly disclosed results | Unclear |
Request point:https://clinicaltrials.servier.com/data-request-portal/login/ | ||
Servier [107] | Study data for approved medications or indications in European Economic Area or US | January 1, 2014 |